Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Aug 2024)

Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort

  • Raffaele Ornello,
  • Matteo Foschi,
  • Federico De Santis,
  • Michele Romoli,
  • Tiziana Tassinari,
  • Valentina Saia,
  • Silvia Cenciarelli,
  • Chiara Bedetti,
  • Chiara Padiglioni,
  • Bruno Censori,
  • Valentina Puglisi,
  • Luisa Vinciguerra,
  • Maria Guarino,
  • Valentina Barone,
  • Marialuisa Zedde,
  • Ilaria Grisendi,
  • Marina Diomedi,
  • Maria Rosaria Bagnato,
  • Marco Petruzzellis,
  • Domenico Maria Mezzapesa,
  • Pietro Di Viesti,
  • Vincenzo Inchingolo,
  • Manuel Cappellari,
  • Cecilia Zivelonghi,
  • Paolo Candelaresi,
  • Vincenzo Andreone,
  • Giuseppe Rinaldi,
  • Alessandra Bavaro,
  • Anna Cavallini,
  • Stefan Moraru,
  • Pietro Querzani,
  • Valeria Terruso,
  • Marina Mannino,
  • Alessandro Pezzini,
  • Giovanni Frisullo,
  • Francesco Muscia,
  • Maurizio Paciaroni,
  • Maria Giulia Mosconi,
  • Andrea Zini,
  • Ruggiero Leone,
  • Carmela Palmieri,
  • Letizia Maria Cupini,
  • Michela Marcon,
  • Rossana Tassi,
  • Enzo Sanzaro,
  • Cristina Paci,
  • Giovanna Viticchi,
  • Daniele Orsucci,
  • Anne Falcou,
  • Simone Beretta,
  • Roberto Tarletti,
  • Patrizia Nencini,
  • Eugenia Rota,
  • Federica Nicoletta Sepe,
  • Delfina Ferrandi,
  • Luigi Caputi,
  • Gino Volpi,
  • Salvatore La Spada,
  • Mario Beccia,
  • Claudia Rinaldi,
  • Vincenzo Mastrangelo,
  • Francesco Di Blasio,
  • Paolo Invernizzi,
  • Giuseppe Pelliccioni,
  • Maria Vittoria De Angelis,
  • Laura Bonanni,
  • Giampietro Ruzza,
  • Emanuele Alessandro Caggia,
  • Monia Russo,
  • Agnese Tonon,
  • Maria Cristina Acciarri,
  • Sabrina Anticoli,
  • Cinzia Roberti,
  • Giovanni Manobianca,
  • Gaspare Scaglione,
  • Francesca Pistoia,
  • Alberto Fortini,
  • Antonella De Boni,
  • Alessandra Sanna,
  • Alberto Chiti,
  • Leonardo Barbarini,
  • Marcella Caggiula,
  • Maela Masato,
  • Massimo Del Sette,
  • Francesco Passarelli,
  • Maria Roberta Bongioanni,
  • Danilo Toni,
  • Stefano Ricci,
  • Eleonora De Matteis,
  • Simona Sacco

DOI
https://doi.org/10.1161/JAHA.124.036275
Journal volume & issue
Vol. 13, no. 16

Abstract

Read online

Background The optimal treatment for acute minor ischemic stroke is still undefined. and options include dual antiplatelet treatment (DAPT), intravenous thrombolysis (IVT), or their combination. We aimed to investigate benefits and risks of combining IVT and DAPT versus DAPT alone in patients with MIS. Methods and Results This is a prespecified propensity score‐matched analysis from a prospective multicentric real‐world study (READAPT [Real‐Life Study on Short‐Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]). We included patients with MIS (National Institutes of Health Stroke Scale score at admission ≤5), without prestroke disability (modified Rankin scale [mRS] score ≤2). The primary outcomes were 90‐day mRS score of 0 to 2 and ordinal mRS distribution. The secondary outcomes included 90‐day risk of stroke and other vascular events and 24‐hour early neurological improvement or deterioration (≥2‐point National Institutes of Health Stroke Scale score decrease or increase from the baseline, respectively). From 1373 patients with MIS, 240 patients treated with IVT plus DAPT were matched with 427 patients treated with DAPT alone. At 90 days, IVT plus DAPT versus DAPT alone showed similar frequency of mRS 0 to 2 (risk difference, 2.3% [95% CI −2.0% to 6.7%]; P=0.295; risk ratio, 1.03 [95% CI 0.98–1.08]; P=0.312) but more favorable ordinal mRS scores distribution (odds ratio, 0.57 [95% CI 0.41–0.79]; P<0.001). Compared with patients treated with DAPT alone, those combining IVT and DAPT had higher 24‐hour early neurological improvement (risk difference, 20.9% [95% CI 13.1%–28.6%]; risk ratio, 1.59 [95% CI 1.34–1.89]; both P<0.001) and lower 90‐day risk of stroke and other vascular events (hazard ratio, 0.27 [95% CI 0.08–0.90]; P=0.034). There were no differences in safety outcomes. Conclusions According to findings from this observational study, patients with MIS may benefit in terms of better functional outcome and lower risk of recurrent events from combining IVT and DAPT versus DAPT alone without safety concerns. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT05476081.

Keywords